OnKure director granted 7,650 stock options

OnKure Therapeutics, Inc. director Valerie Malyvanh Jansen received a grant of stock options covering 7,650 shares of Class A Common Stock.

Accepted by SEC EDGAR 06/08/2026 - 06:25 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

OnKure Therapeutics, Inc. director Valerie Malyvanh Jansen received a grant of stock options covering 7,650 shares of Class A Common Stock. The options have an exercise price of $4.30 per share and expire on June 3, 2036.

All 7,650 option shares will vest 100% on the earlier of June 4, 2027 or the day prior to OnKure’s next annual meeting of stockholders, if she continues as a service provider through that date. Following this grant, she holds 7,650 options directly.

Insider Trade Summary

Grant/Award: 7,650 shares

Grant/Award 1 txn

Insider Jansen Valerie Malyvanh

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	7,650	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 7,650 contracts (Direct)

Footnotes (1)

1. F1. 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

Key Figures

Options granted: 7,650 options Exercise price: $4.30 per share Expiration date: June 3, 2036 +3 more

6 metrics

Options granted 7,650 options Stock Option (right to buy) granted to director

Exercise price $4.30 per share Conversion or exercise price of stock options

Expiration date June 3, 2036 Option expiration date

Underlying shares 7,650 shares Class A Common Stock underlying the options

Post-transaction options held 7,650 options Total derivative securities following the grant

Vesting condition date June 4, 2027 100% vesting on earlier of this date or day before next annual meeting

Key Terms

Stock Option (right to buy), Class A Common Stock, exercise price, annual meeting of stockholders

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Class A Common Stock financial

"underlying_security_title: "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

exercise price financial

"conversion_or_exercise_price: "4.3000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual meeting of stockholders financial

"the date of the Issuer's next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did OnKure Therapeutics (OKUR) disclose in this Form 4 filing?

OnKure Therapeutics disclosed that director Valerie Malyvanh Jansen received a grant of stock options for 7,650 shares of Class A Common Stock at a $4.30 exercise price, expiring June 3, 2036, as part of her equity compensation.

How many OnKure (OKUR) stock options were granted to Valerie Malyvanh Jansen?

She was granted stock options for 7,650 shares of OnKure’s Class A Common Stock. These options give her the right to buy those shares at a fixed $4.30 exercise price if the options vest and are exercised in the future.

What is the exercise price and expiration date of the new OKUR stock options?

The stock options have an exercise price of $4.30 per share and expire on June 3, 2036. This means she can purchase shares at $4.30 any time after vesting and before the June 3, 2036 expiration, subject to plan terms.

When do Valerie Malyvanh Jansen’s OnKure (OKUR) options vest?

All 7,650 options will vest 100% on the earlier of June 4, 2027 or the day prior to OnKure’s next annual meeting of stockholders, provided she continues as a service provider through the applicable vesting date, according to the footnote.

How many OnKure (OKUR) derivative securities does the director hold after this grant?

After this transaction, she holds 7,650 stock options directly. These options represent rights to acquire 7,650 shares of Class A Common Stock if exercised after vesting, under the terms of the company’s equity incentive arrangements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jansen Valerie Malyvanh

(Last) (First) (Middle)

C/O ONKURE THERAPEUTICS, INC.

6707 WINCHESTER CIRCLE, SUITE 400

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OnKure Therapeutics, Inc. [ OKUR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.3	06/04/2026		A		7,650		(1)	06/03/2036	Class A Common Stock	7,650	$0	7,650	D

Explanation of Responses:

1. 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

	/s/ Rogan Nunn, by power of attorney	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)